DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
WALTHAM, Mass., March 28, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- H.C. Wainwright Global Life Sciences Conference – Monte Carlo, Monaco (April 8-10, 2018)
Jonathan Lieber, Histogenics’ CFO, will present a corporate overview on Tuesday, April 10, 2018 at 11:55a.m. CEST / 5:55 a.m. EDT.
- Alliance for Regenerative Medicine 6th Annual Cell and Gene Investor Day – New York, NY (April 17, 2018)
Sponsored by the Alliance for Regenerative Medicine, the conference provides institutional, strategic and venture investors a unique opportunity to gain insight into over 30 leading cell and gene therapy companies. Mr. Lieber will present a corporate overview on Tuesday, April 17, 2018 at 9:10 a.m. EDT.
To access live audio webcasts of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
[email protected]
